EB Treatment

We've had the privilege of working with patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB), an uncommon blistering skin ailment. Our participation in a phase 3 clinical trial marked a milestone as we contributed data to the first-ever FDA approved topical gene therapy for this condition, now commercially known as Vyjuvek. Witnessing the remarkable success of B-VEC firsthand has been truly inspiring. Over the past 3 years, we've collaborated closely with a group of DEB patients and are now thrilled to extend this treatment opportunity to a wider audience. Our skilled providers will assess your candidacy for this transformative treatment, ensuring the best possible outcome for you.